Home > Insider Trading > Filing (0001179110-20-000557)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
861838	Idera Pharmaceuticals Inc.	IDRA	Biological Products, (No Disgnostic Substances) (2836)	043072298

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1556327	J. John Kirby	C/O Idera Pharmaceuticals, Inc. 505 Eagleview Blvd., Suite 212 Exton PA 19341	Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2020-01-07	911	$1.78	16,437	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct

Footnotes

The Form 4 filed on January 10, 2020 did not include the Deemed Execution Date in Column 2A and corresponding footnote disclosure. This amendment to the Form 4 is being filed to include this information for the reported transaction.
In accordance with terms of the RSU agreement, the "sell to cover" provision is intended to comply with the requirements of Rule 10b5-1(c)(1) under the Exchange Act and be interpreted to comply with the requirements of Rule 10b5-1(c) under the Exchange Act.
Represents the number of shares of Issuer common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 2,562 Restricted Stock Units ("RSUs") on January 3, 2020. This sale is mandated by the Issuer's election under its 2013 Stock Incentive Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $1.76 to $1.82 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Of the reported shares, 7,688 shares are represented by unvested RSUs.